Ernexa Therapeutics Inc. 10-Q

Item 5. Other Information . None Item 6. Exhibits Exhibit Description Incorporated By Reference 10.1 Securities Purchase Agreement, dated as of July 13, 2023, by and among Eterna Therapeutics Inc. and the purchasers party thereto. Exhibit 10.1 to Form 8-K filed on July 18, 2023 10.2 Registration Rights Agreement, dated as of July 13, 2023, by and among Eterna Therapeutics Inc. and the purchasers party thereto. Exhibit 10.4 to Form 8-K filed on July 18, 2023 10.3 Form of Senior Convertible Note. Exhibit 10.2 to Form 8-K filed on July 18, 2023 10.4 Form of Common Stock Purchase Warrant. Exhibit 10.3 to Form 8-K filed on July 18, 2023 10.5 First Amendment to Exclusive License Agreement, dated as of July 12, 2023, by and between Eterna Therapeutics Inc. and Factor Bioscience Limited. Exhibit 10.1 to Form 8-K filed on July 13, 2023 31.1 Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Filed herewith 31.2 Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 Filed herewith 32.1 Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Furnished herewith 35 Table of Contents 32.2 Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Furnished herewith 101.INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document). Filed herewith 101.SCH Inline XBRL Taxonomy Extension Schema Document Filed herewith 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document Filed herewith 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document Filed herewith 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document Filed herewith 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document Filed herewith 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). 36 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ETERNA THERAPEUTICS INC. Date: November 13, 2023 By: /s/ Matthew Angel Matthew Angel Chief Executive Officer and President (Principal Executive Officer) Date: November 13, 2023 By: /s/ Sandra Gurrola Sandra Gurrola Vice President of Finance (Principal Financial Officer and Principal Accounting Officer) 37